Three-Drug immune cocktail takes on pancreatic cancer

NCT ID NCT05419479

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining three immunotherapy drugs (domvanalimab, zimberelimab, and APX005M) can safely control metastatic pancreatic cancer. The trial enrolls 46 people whose cancer has spread and standard treatments have stopped working. Researchers will monitor side effects and measure tumor shrinkage every 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
domvanalimab, zimberelimab, and APX005M (immunotherapy drugs)
What this could lead to
If it works, this could point toward a new treatment option that helps control metastatic pancreatic cancer by using the immune system to fight the tumor.
What could go wrong
This is an early-phase trial (phase 1/2) with only 46 participants, so results may not apply to everyone. The study is currently suspended, and immunotherapy can cause serious immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PANCREAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.